Hazem Elkady

2.6k citations

94 papers · 2.3k indexed · h-index 30

Organic Chemistry top 1%
Molecular Biology top 10%
Toxicology top 0.2%
Oncology top 10%
Computational Theory and Mathematics top 2%

Co-authors: Ibrahim H. Eissa Eslam B. Elkaeed Ahmed M. Metwaly Ibrahim M. Ibrahim Dalal Z. Husein Aisha A. Alsfouk Alaa Elwan Mohammed S. Taghour
Topics: Synthesis and biological activity (51 papers)Bioactive Compounds and Antitumor Agents (31 papers)Angiogenesis and VEGF in Cancer (27 papers)
Cited by: Toxicology Organic Chemistry Computational Theory and Mathematics
Journals: PLoS ONE Scientific Reports International Journal of Molecular Sciences
Partner nations: Egypt Saudi Arabia Indonesia

In The Last Decade

Hazem Elkady

85 papers receiving 2.3k citations

Peers

Countries citing papers authored by Hazem Elkady

Since Specialization

Citations

This map shows the geographic impact of Hazem Elkady's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hazem Elkady with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hazem Elkady more than expected).

Fields of papers citing papers by Hazem Elkady

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hazem Elkady. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hazem Elkady. The network helps show where Hazem Elkady may publish in the future.

Co-authorship network of co-authors of Hazem Elkady

This figure shows the co-authorship network connecting the top 25 collaborators of Hazem Elkady. A scholar is included among the top collaborators of Hazem Elkady based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hazem Elkady. Hazem Elkady is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	New nicotinamide–thiadiazol hybrids as VEGFR-2 inhibitors for breast cancer therapy: design, synthesis and in silico and in vitro evaluation 2025 ·RSC Advances ·Walid E. Elgammal,Hazem Elkady,Reda G. Yousef,Wagdy M. Eldehna,Dalal Z. Husein,(unknown),Bshra A. Alsfouk,Eslam B. Elkaeed,Ibrahim H. Eissa,Ahmed M. Metwaly	4
2	Small-molecule strategies to combat antibiotic resistance: mechanisms, modifications, and contemporary approaches 2025 ·RSC Advances ·Hazem Elkady,(unknown),Mohamed M. Khalifa	0
3	Targeting VEGFR-2 in breast cancer: synthesis and in silico and in vitro characterization of quinoxaline-based inhibitors 2025 ·RSC Advances ·Ibrahim H. Eissa,Alaa Elwan,(unknown),Dalal Z. Husein,(unknown),Aisha A. Alsfouk,Eslam B. Elkaeed,Hazem Elkady,Ahmed M. Metwaly	6
4	Development of New Thiadiazole Derivatives as VEGFR‐2 Inhibitors With Anticancer and Proapoptotic Activities 2025 ·Archiv der Pharmazie ·Hazem Elkady,Walid E. Elgammal,Mohamed M. Khalifa,(unknown),Ahmed S. Ibrahim,(unknown),Bshra A. Alsfouk,Eslam B. Elkaeed,Ahmed M. Metwaly,Ibrahim H. Eissa	2
5	Development of novel furan-based VEGFR-2 inhibitors and apoptotic inducers for colorectal cancer 2025 ·Future Medicinal Chemistry ·Eslam B. Elkaeed,(unknown),Hazem Elkady,Reda G. Yousef,(unknown),(unknown),Esmail M. El‐Fakharany,Aisha A. Alsfouk,Ahmed M. Metwaly,Ibrahim H. Eissa	0
6	New thiazolidine-2,4-diones as potential anticancer agents and apoptotic inducers targeting VEGFR-2 kinase: Design, synthesis, in silico and in vitro studies 2024 ·Biochimica et Biophysica Acta (BBA) - General Subjects ·Hazem Elkady,Hazem A. Mahdy,Mohammed S. Taghour,Mohammed A. Dahab,Alaa Elwan,Mohamed Hagras,(unknown),Ibrahim M. Ibrahim,Dalal Z. Husein,Eslam B. Elkaeed,Aisha A. Alsfouk,Ahmed M. Metwaly,Ibrahim H. Eissa	13
7	Integrated in silico and in vitro discovery of a new anticancer thiadiazole analog targeting VEGFR-2 2024 ·Journal of Molecular Structure ·Ibrahim H. Eissa,Hazem Elkady,Walid E. Elgammal,Hazem A. Mahdy,Eslam B. Elkaeed,Aisha A. Alsfouk,Ibrahim M. Ibrahim,Dalal Z. Husein,Ahmed M. Metwaly	13
8	Design, synthesis, in vitro, and in silico studies of new thiadiazol derivatives as promising VEGFR-2 inhibitors and apoptosis inducers 2024 ·Journal of Molecular Structure ·Hazem A. Mahdy,Hazem Elkady,Walid E. Elgammal,Eslam B. Elkaeed,Aisha A. Alsfouk,(unknown),Dalal Z. Husein,Mohamed A. Elkady,Ahmed M. Metwaly,Ibrahim H. Eissa	15
9	Design and In Silico and In Vitro Evaluations of a Novel Nicotinamide Derivative as a VEGFR-2 Inhibitor 2024 ·Journal of Chemistry ·Ibrahim H. Eissa,(unknown),Reda G. Yousef,Hazem Elkady,Eslam B. Elkaeed,Bshra A. Alsfouk,Ibrahim M. Ibrahim,Ahmed M. Metwaly,Dalal Z. Husein	2
10	Design and synthesis of new nicotinamides as immunomodulatory VEGFR-2 inhibitors and apoptosis inducers 2024 ·Future Medicinal Chemistry ·Reda G. Yousef,Ibrahim H. Eissa,Hazem Elkady,Taha Mehany,(unknown),Mohamed M. Radwan,Mahmoud A. ElSohly,(unknown),Alaa Elwan,Mohamed Ayman El‐Zahabi	4
11	New thiazolidine-2,4-diones as effective anti-proliferative and anti-VEGFR-2 agents: Design, synthesis, in vitro, docking, MD simulations, DFT, ADMET, and toxicity studies 2023 ·Computational Biology and Chemistry ·Hazem Elkady,(unknown),(unknown),Mohammed S. Taghour,Mohammed A. Dahab,Hazem A. Mahdy,Alaa Elwan,Hanan Al-Ghulikah,Eslam B. Elkaeed,Ibrahim M. Ibrahim,Dalal Z. Husein,Ahmed M. Metwaly,Ibrahim H. Eissa	16
12	Design, synthesis, anti-proliferative evaluation, docking, and MD simulation studies of new thieno[2,3-d]pyrimidines targeting VEGFR-2 2023 ·RSC Advances ·Souad A. El‐Metwally,Hazem Elkady,Mohamed Hagras,Dalal Z. Husein,Ibrahim M. Ibrahim,Mohammed S. Taghour,Hesham A. El‐Mahdy,Ahmed Ismail,Bshra A. Alsfouk,Eslam B. Elkaeed,Ahmed M. Metwaly,Ibrahim H. Eissa	15
13	A Theobromine Derivative with Anticancer Properties Targeting VEGFR‐2: Semisynthesis, in silico and in vitro Studies 2023 ·ChemistryOpen ·Ibrahim H. Eissa,Reda G. Yousef,Hazem Elkady,Eslam B. Elkaeed,Aisha A. Alsfouk,Dalal Z. Husein,Ibrahim M. Ibrahim,Mohamed M. Radwan,Ahmed M. Metwaly	11
14	Rationale design and synthesis of new apoptotic thiadiazole derivatives targeting VEGFR-2: computational and in vitro studies 2023 ·RSC Advances ·Walid E. Elgammal,Hazem Elkady,Hazem A. Mahdy,Dalal Z. Husein,Aisha A. Alsfouk,Bshra A. Alsfouk,Ibrahim M. Ibrahim,Eslam B. Elkaeed,Ahmed M. Metwaly,Ibrahim H. Eissa	20
15	Design, synthesis, molecular docking, ADMET studies, and biological activity evaluation of new 2-({[3-aryl-1,2,4-oxadiazol-5-yl)methyl]thio}-1H-benzimidazoles and 6-amino-6-aryl-5,6-dihydro[1,6,2,4]oxathiadiazocino[4,5-a]benzimidazol-3(2H)-ones 2023 ·Journal of Molecular Structure ·Mohamed H. Sharaf,Amr H. Moustafa,Rami J. Obaid,Abdullah Yahya Abdullah Alzahrani,Moustafa O. Aboelez,Hazem Elkady,Noof A. Alenazi,Mounir A. A. Mohamed,Jabir H. Al‐Fahemi,Ziad Moussa,Omran A. Omran,Saleh A. Ahmed	8
16	Modified Benzoxazole-Based VEGFR-2 Inhibitors and Apoptosis Inducers: Design, Synthesis, and Anti-Proliferative Evaluation 2022 ·Molecules ·Alaa Elwan,Abdallah E. Abdallah,Hazem A. Mahdy,Mohammed A. Dahab,Mohammed S. Taghour,Eslam B. Elkaeed,Ahmed B. M. Mehany,(unknown),(unknown),Aisha A. Alsfouk,Hazem Elkady,Ibrahim H. Eissa	51
17	A Multistage In Silico Study of Natural Potential Inhibitors Targeting SARS-CoV-2 Main Protease 2022 ·International Journal of Molecular Sciences ·Eslam B. Elkaeed,Ibrahim H. Eissa,Hazem Elkady,(unknown),(unknown),Aisha A. Alsfouk,Alaa Elwan,Ahmed M. Metwaly	44
18	Design, synthesis, anti-proliferative evaluation, docking, and MD simulations studies of new thiazolidine-2,4-diones targeting VEGFR-2 and apoptosis pathway 2022 ·PLoS ONE ·Mohammed S. Taghour,Hazem Elkady,Wagdy M. Eldehna,Nehal M. El‐Deeb,Ahmed M. Kenawy,Eslam B. Elkaeed,Bshra A. Alsfouk,Mohamed S. Alesawy,Dalal Z. Husein,Ahmed M. Metwaly,Ibrahim H. Eissa	40
19	Discovery of new VEGFR-2 inhibitors based on bis([1, 2, 4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as anticancer agents and apoptosis inducers 2021 ·Journal of Enzyme Inhibition and Medicinal Chemistry ·Nawaf A. Alsaif,Mohammed S. Taghour,Mohammed M. Alanazi,Ahmad J. Obaidullah,Abdulrahman A. Almehizia,(unknown),(unknown),Alaa Elwan,Hazem Elkady	57
20	Design, synthesis, in silico ADMET profile and GABA‐A docking of novel phthalazines as potent anticonvulsants 2019 ·Archiv der Pharmazie ·Abdel‐Ghany A. El‐Helby,Rezk R. Ayyad,Mohamed F. Zayed,Hamada S. Abulkhair,Hazem Elkady,Khaled El‐Adl	53

About Hazem Elkady

Hazem Elkady is a scholar working on Toxicology, Organic Chemistry and Computational Theory and Mathematics, having authored 94 papers that have together received 2.3k indexed citations. Recurring topics across this work include Synthesis and biological activity (51 papers), Bioactive Compounds and Antitumor Agents (31 papers) and Angiogenesis and VEGF in Cancer (27 papers). The work is most often cited by research in Toxicology (454 citations), Organic Chemistry (1.5k citations) and Computational Theory and Mathematics (350 citations). Hazem Elkady has collaborated with scholars based in Egypt, Saudi Arabia and Indonesia. Frequent co-authors include Ibrahim H. Eissa, Eslam B. Elkaeed, Ahmed M. Metwaly, Ibrahim M. Ibrahim, Dalal Z. Husein, Aisha A. Alsfouk, Alaa Elwan, Mohammed S. Taghour, Reda G. Yousef and Hazem A. Mahdy. Their work appears in journals such as PLoS ONE, Scientific Reports and International Journal of Molecular Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact